Looking into the uh results of the uh Wheeler and investment study, uh, if I have to uh choose the, the patient to be treated with brain soctib, I would go to uh a patient with, uh, uh. Two or more exacerbations in the past year, but also to the patient with maybe one exacerbation, but referring symptoms. Uh, I think symptoms burden is quite important. Cough, sputum production, dyspnea are important symptoms that are related to the number of exacerbation, but also to the quality of life and probably also. At the end of the day, the burden of the disease, so exacerbation are clearly important, but also what the patient reports is also important. Symptoms are important, and we showed in a paper published by the first name Abel clearly showed that symptoms are important because they are a measure of inflammation in the airways. So I think this leads to how to manage the patient. When we prescribe or will prescribe benzotib in this kind of patient, what are the first point to see the effect of renzo? Clearly it's not the number of exacerbation because we have to say to the patient that in 3 months something will happen to give us the sense of the effect of the drug. And probably the change of symptoms are quite important. Sputum production could be one of the the results of the of the of the treatment. Dyspnea, the reduction in dyspnea could be another point, and related to sputum cough is important. So symptoms, I think, is one of the main points. Then clearly exacerbation and pulmonary function. This is another important point. Uh, if you look at the data from aspirin, particularly the 25 mg, uh, in 6 to 8 weeks lead to an improvement in lung function that then can stay uh over time. But I think this is another, another interesting tool to, to be followed to define the responding patient. So, if I have to summarize, uh, clearly, the patient to be included is at least one exacerbation and with symptoms, uh, as indicated by the, the very last ERS guidelines. And the other point is pulmonary function that can be followed in a, in, in, in a longer time. So the reduction in symptoms, the improvement in lung function could be uh some tools to be followed and to identify the responder patient.
Presenter
